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It is known that vitamin D3 metabolites and transforming growth factor 03 (TGF-03)
regulate proliferation and differentiation of chondrocytes isolated from the growth zone or
resting zone of rat costochondral cartilage. It was hypothesized that both TGF-03 and the
vitamin D metabolites play a role in signal transduction in the rat costochondral chondrocyte
model and that the regulation of protein kinase C by these metabolites would be cell
maturation-dependent. Confluent, fourth passage cultures of growth zone and resting zone
chondrocytes were treated with vitamin D3 metabolites for up to 24 hours, lysed, and the cell
extracts assayed for protein kinase C (PKC) specific activity using a specific peptide substrate.
The addition of 1,25-(OH)2D3 to growth zone chondrocyte cultures resulted in a rapid, dose-
dependent stimulation of PKC specific activity. The effect was significant at 10-9-10-7M
1,25-(OH) 2D3 and began 3 minutes after addition of hormone and continued for an additional
90 minutes. In contrast, 1,25-(OH) 2D3 had no effect on PKC specific activity in resting zone
V
chondrocyte cultures. The addition of 24,25-(OH) 2D 3 to resting zone chondrocyte cultures
also produced PKC activation. The response was significant at 10-8-10- 7M 24,25-(OH) 2D3
and slower than that seen for 1,25-(OH) 2D3 and the growth zone cells. Increases in PKC
specific activity were detectable 90 minutes after addition of hormone and lasted up to 360
minutes. 24,25-(OH)2 D3 had no effect on PKC specific activity in cultures of growth zone
cells at all times and concentrations examined. Pretreatment of the cultures with U73122, a
phospholipase C inhibitor, decreased 1,25-(OH) 2D3-stimulated PKC specific activity, but had
no effect upon 24,25-(OH) 2D3-induced activity. The tyrosine kinase inhibitor, genistein, did
not inhibit the PKC specific activity response in cultures treated with either of the vitamin D3
metabolites. Neither actinomycin D nor cycloheximide affected 1,25-(OH) 2D3-induced PKC
specific activity in growth zone chondrocyte cultures, while both compounds inhibited 24,25-
(OH)2D3 -induced activity in resting zone chondrocyte cultures. The results of this portion of
the study indicate that vitamin D metabolites stimulate PKC specific activity in a metabolite-
and cell-maturation-specific manner. Effects of 1,25-(OH) 2D3 appear to be nongenomic,
whereas the effects of 24,25-(OH)2D3 probably involve a genomic mechanism.
In contrast, addition of transforming growth factor-beta (TGF-13) to cultures of both
resting zone and growth zone chondrocytes produced dose-dependent increases in PKC
specific activity. Significant effects on enzyme activity were observed 6 hours after addition
of growth factor with maximal stimulation found at 12 hours; baseline levels of activity
returned after 24 hours. Neither the phospholipase C inhibitor, U73122, nor the tyrosine
kinase inhibitor, genistein, significantly reduced the response to TGFO3. However, treatment
of cultures with actinomycin D or cycloheximide prior to addition of TGFJ3 resulted in a dose-
dependent inhibition of TGFO3-stimulated PKC specific activity in both growth zone and
resting zone chondrocytes. The time-course of activation and insensitivity to U73122 suggest
that phospholipase C-mediated events are not involved. Similarly, since genistein has no
effect, tyrosine kinases are probably not involved in TGFO3-induced PKC specific activity in
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chondrocytes. Rather, the reduction in PKC specific activity observed when TGFO3 is
administered along with actinomycin D or cycloheximide indicates that new gene expression
and protein synthesis are required for the response. Because an earlier and more prolonged
response was seen in resting zone chondrocytes than in growth zone chondrocytes, the effect
of TGFP3 on PKC specific activity appears to be cell maturation-dependent. These results
suggest that the effect of TGFO on chondrocytes may be mediated by PKC. However, since
the effect is very slow, it may require new PKC production. Moreover, the classic mechanism
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I. INTRODUCTION
A. Signal Transduction And Protein Kinase C:
Communication between the extracellular and intracellular compartments is critical to
normal functioning of cells, tissues and the entire organism. The biochemical pathways used
for the transduction of signals into the cell has been an area of considerable research. The
elucidation of signal transduction pathways used by chondrocytes and osteoblasts will have
significant implications in cartilage repair, fracture healing, periodontal regenerative
procedures, and endosseous implants. This thesis will examine the signal transduction
pathways utilized by rat costochondral chondrocytes in response to treatment with vitamin D3
metabolites and transforming growth factor-beta (TGF-03).
Hormones and peptide growth factors influence their target cells by binding to specific
receptors in the plasma membrane (Felig et aL, 1981). Sutherland et al., (1966) suggested
that the cell membrane serves as the site of action for hormones. They observed that the
interaction of catecholamines with the plasma membrane of pigeon erythrocytes led to the
activation of adenylate cyclase. Sutherland's concept of hormone action, the first messenger,
stimulating cAMP or some other mediator as a second (intracellular) messenger is central to
the study of signal transduction. Other membrane enzymes, regulated by binding of primary
messengers, are involved in inositol turnover, sodium-potassium ATPase activity, membrane-
bound protein kinases, methyltransferases involved in phospholipid methylation, and
phospholipases responsible for deacylation of membrane phospholipids. Membrane
phospholipids provide precursors, such as arachidonic acid, for prostaglandin, thromboxane,
and prostacyclin biosynthesis which are important inflammatory mediators. Thus, there are
numerous pathways by which a hormone or growth factor could influence intracellular
metabolism (Felig et al., 1981).
2Protein kinases are enzymes that catalyze the transfer of phosphate groups from one
compound to another (Lehninger, 1982). Protein kinase C (PKC) has been intensively studied
because its believed to be involved in signal transduction and, possibly, tumorigenesis.
Originally identified in rat brain extracts as a calcium and phospholipid activated protein
kinase (Takai, et al., 1979), it was ultimately linked to signal transduction because
diacylglycerol, one of the early products of inositol phospholipid breakdown, greatly increased
the affinity of PKC for Ca12 and its activity (Takai et al., 1979).
Evidence that activation of PKC was linked to signal transduction has primarily come
from experiments with platelets (Kawahara et al., 1980). Kawahara et al., showed that
platelets, when stimulated, produce diacylglycerol containing arachidonic acid, and that this
reaction is accompanied by the disappearance of inositol phospholipids. This appearance of
diacylglycerol in membranes was found to always be associated with the activation of PKC.
Several phorbol esters, such as 12-O-tetradecanoylphorbol-13-acetate (TPA), are
potent tumor promoters. Many studies, with various cell types, suggest that phorbol esters
act on the cell membrane surface (Blumberg, 1980). Studies by Castagna et al., (1982) have
provided evidence that PKC is a target for phorbol esters since these agents directly activate
this enzyme. Like diacylglycerol, TPA increases the affinity of PKC for Ca2+, resulting in
enzyme activation.
Currently, ten isoforms of PKC have been identified. Four isoforms (alpha, beta-I, beta-
II and gamma), called the classical protein kinases, were identified by screening
complementary cDNA libraries. Subsequently, six other isoforms (delta, epsilon, lambda, nu,
theta, and zeta) have been identified. In rat, gamma and epsilon isoforms are found solely in
brain and spinal cord, whereas beta-I, beta-II and delta isoforms are found in numerous organ
systems. The alpha isoform of PKC is the most widely distributed. This enzyme consists of a
single polypeptide chain with a molecular weight of 77 kDa. All isoforms of PKC
phosphorylate proteins on serine and threonine residues (Nishizuka, 1984).
3PKC isoforms alpha, beta-I, beta-II and gamma have been shown to be
Ca 2+/phospholipid/diacylglycerol (DAG)-dependent protein kinases (Knopf et al., 1986,
Kikkawa et al., 1987). PKC activation is thought to be involved in a variety of cell responses,
including cell proliferation, gene expression, membrane transport, and the excretion of
hormones and neurotransmitters (Nishizuka, 1984). While these isoforms constitute a family,
studies show that there are functional differences between the members. These isoforms
would not be expected to function interchangeably, but to act in parallel to transduce specific
signals to the cell (Parker et al., 1989).
van Leeuwen et al., (1992) have shown that 1,25-(OH) 2D3 stimulates osteocalcin
synthesis by osteoblast-like cells and that this was inhibited 30-70% in the presence of PKC
inhibitors. These results showed for the first time, that PKC is involved in mediating the effect
of 1,25-(OH) 2D3 on bone cells. Obeid et al., (1990) treated human promyelocytic leukemia
cells with 1,25-(OH) 2D 3 and found that mRNA for both PKC alpha and beta was increased.
This was the first report of transcriptional activation of PKC, and may be a mechanism for the
long term alteration of the PKC pathway. Yada et al., (1989) found that only 1-alpha-25-
(OH)2D3 induced the formation of a mature envelope in murine keratinocytes. Inhibition of
PKC by pretreatment with H-7, a specific inhibitor of PKC, caused significant suppression of
the vitamin D3 affect. These findings suggest that PKC is involved in mediating the effect of
vitamin D metabolites on these cells.
Ohtsuki et al., (1992) demonstrated that transforming growth factor-0 (TGF03) induced
expression of transcription factors and prevented phosphorylation of the retinoblastoma
susceptibility gene product. These responses were blocked by the protein kinase C inhibitors
H7, H8 and H9. Wrenn et al., (1993) investigated the role of PKC in the action of TGF-03 on
cultured embryonic avian vascular smooth muscle from different tissues. A fifteen minute
exposure to TGF-03 significantly increased PKC activity in these cells. TGF-P3 also increased
the production of diacylglycerol (DAG) as early as 15 seconds after addition. DAG is
considered to be a second messenger molecule responsible for activation of PKC.
Chakrabarty (1992) showed that induction of carcinoembryonic antigen by TGF-13 1 was
associated with PKC activation. Treatment of cells with the PKC inhibitors calphostin C or
H-7 blocked activation of the carcinoembryonic antigen as well as PKC activity. The
diacylglycerol kinase inhibitor, R59 022, and the G-protein inhibitors cholera toxin and
pertussis toxin had no affect. It was concluded that TGF-13 1 regulates carcinoembryonic
antigen expression through a pathway that utilizes PKC. These studies strongly suggest a
significant role for PKC in TGF-13-mediated signal transduction.
B. Endochondral Ossification and Vitamin D Metabolites:
Endochondral bone formation involves the differentiation of mesenchymal stem cells into
chondrocytes and calcification of the cartilaginous matrix they form. Long bone growth,
fracture repair and bone induction all require endochondral ossification and therefore
calcification of cartilage is critical (Glowacki, 1982; Ksiazek and Moskalewski, 1983). During
long bone development the cartilaginous epiphysis is separated from the diaphysis by the
epiphyseal growth plate. Chondrocytes in the growth plate proliferate, mature, hypertrophy
and calcify their extracellular matrix (Boskey, 1981, Anderson, 1969). Rat costochondral
chondrocyte cultures have been used to understand the differentiation and regulation of
cartilage cells during endochondral ossification (Boyan et al., 1992). These cultures have
proven to be an excellent model for studying the genomic and nongenomic effects of vitamin
D metabolites, such as 1,25-(OH) 2D3 and 24,25-(OH)2D3, on resting zone and growth zone
chondrocytes (Boyan et al., 1988; Langston et al., 1990; Schwartz et al., 1989; Swain et al.,
1992).
Chondrocytes of the proliferative zone contain extracellular matrix vesicles that are filled
with a granular material (Boskey, 1981). These matrix vesicles appear to be involved in the
calcification of cartilage (Anderson, 1969, 1976). Initially, crystals can be observed along the
inner surface of the matrix vesicle membrane. The matrix vesicle then ruptures and the
5mineral is directly deposited into the matrix (Brighton and Hunt, 1976). The vesicles are
derived from the plasma membrane of the chondrocyte (Cecil and Anderson, 1978), and
contain numerous enzymes which participate in mineralization, either by promoting crystal
formation, or by modifying the extracellular matrix (Boyan, 1988).
Vitamin D has been shown to be essential for proper endochondral ossification (Raisz
and Kream, 1983a and b). Vitamin D, or cholecalciferol, is made in the skin from an inactive
form, 7-dehydrocholesterol, by reactions initiated by sunlight. Vitamin D is hydroxylated first
in the liver and then in the kidney to an active form, 1,25-dihydroxycholecalciferol, which is
important for calcium and phosphate metabolism (Lehninger, 1982). In vitamin D deficient
chicks the growth zone of the cartilage fails to mineralize. When given vitamin D (Atkin et
al., 1985), or when given calcium (Balsan et al., 1986), the growth plate rapidly heals.
The response of bone and cartilage cells to vitamin D metabolites is a function of their
state of differentiation. 1,25-dihydroxyvitamin D3 exerts specific effects on the alkaline
phosphatase activity of osteosarcoma cells (Majeska and Rodan, 1982), human bone-derived
osteoblastic cells (Beresford et al., 1986), and rat calvaria (Canalis and Lian, 1985) which are
dependent on the state of cell maturation. 1,25-dihydroxyvitamin D 3 and 24,25-
dihydroxyvitamin D 3 exert opposing effects on alkaline phosphatase activity in chick growth
plate chondrocytes (Hale et al., 1986). As alluded to above, rat costochondral chondrocytes
have been used to understand the differentiation and regulation of cartilage -cells during
endochondral ossification (Boyan et al., 1992). Using this model, Schwartz et al. (1989),
studied the effect of vitamin D metabolites on collagen synthesis and cell proliferation. They
showed that addition of 1,25-(OH)2D3 to growth zone chondrocytes increased collagen
synthesis, but decreased collagen synthesis in resting zone cells. The addition of 24,25-
(OH) 2D 3 decreased collagen synthesis in resting zone chondrocytes and had no effect on
growth zone cells. 1,25-(OH) 2D3 and 24,25-(OH) 2D3 both inhibited (3H)-thymidine
incorporation in resting and growth zone chondrocytes, which correlated with a decrease in
6cell number. Langston et al. (1990), showed that calcium flux in chondrocyte cultures treated
with either 1,25-(OH) 2D3 or 24,25-(OH) 2D3 was cell maturation dependent. Schwartz et al.
(1988a, 1988b), also showed a differential response by growth zone and resting zone
chondrocytes to the addition of 1,25-(OH)2D3. In growth zone cultures, alkaline phosphatase
and phospholipase A2 specific activities were increased, whereas in resting zone cultures, this
form of vitamin D had no effect on alkaline phosphatase or phospholipase A2 specific activity.
Schwartz et al. (1993), showed that 1,25-(OH)2D3 stimulated prostaglandin E2 (PGE2)
production by growth zone cells in a dose-dependent manner, but had no effect on PGE2
production by resting zone cells. In contrast, 24,25-(OH) 2D3 inhibited PGE2 production in
resting zone cells and had no effect on growth zone cells.
The effect of 1,25-(OH) 2D3 and 24,25-(OH)2D3 have also been measured in isolated
matrix vesicles and compared with those of the plasma membrane isolated from rat
costochondral chondrocyte cultures (Schwartz et al., 1988). 1,25-(OH) 2D3 was found to
stimulate alkaline phosphatase and phospholipase A2 specific activities in matrix vesicles
produced by growth zone chondrocytes, but had no effect on the plasma membrane fraction,
or on the matrix vesicles or plasma membranes isolated from resting zone chondrocyte
cultures. 24,25-(OH) 2D 3, however, stimulated alkaline phosphatase activity in matrix vesicles
from resting zone chondrocytes, but had no effect on plasma membranes isolated from the
same cells. Growth zone chondrocyte derived matrix vesicle or plasma membrane enzymes
were unaffected by 24,25-(OH) 2D3. Glaser and Conrad (1981) demonstrated that matrix
vesicles from the growth zone of chick embryos differed in alkaline phosphatase activity from
those of the resting zone.
Both 1,25-(OH) 2D3 and 24,25-(OH) 2D3 regulate membrane enzymes in a non-genomic
manner as well. 4 5Ca flux (Langston et al., 1990), fatty acid metabolism (Schwartz et al.,
1990; Swain et al., 1992), and membrane fluidity (Swain et al., 1993) are regulated rapidly
and directly by vitamin D metabolites. Nongenomic effects of 1,25-(OH) 2D 3 have been
7reported in other systems as well. 1,25-(OH) 2D3 has been shown to stimulate the hydrolysis
of membrane phosphoinositides in enterocytes (Lieberherr et al., 1989; Wali et al., 1990),
keratinocytes (McLaughlin et al., 1987; Tang et al., 1987), osteoblasts (Oshima et al., 1987)
and parathyroid cells (Bourdeau et at., 1990). Breakdown of phosphoinositides generates
second messengers such as inositol triphosphate (IP3), which releases Ca2+ from intracellular
stores and diacylglycerol (Berridge, 1987). This biochemical pathway would be consistent
with the hypothesis that PKC plays a significant role in signal transduction mediated by
vitamin D metabolites.
C. Transforming Growth Factor-Beta (TGF-B):
TGF-P3 belongs to a family of polypeptide growth factors that include a number of
homologous dimeric proteins which share a high degree of homology. Other related members
of the family are the activins and inhibins (which modulate the in vitro secretion of follicle-
stimulating hormone), Mullerian-inhibiting substance (which inhibits the formation of
Mullerian ducts in male embryos) and products of the decapentaplegic gene complex in
Drosophila. The amino acid sequences of these proteins are approximately 25-35%
homologous with TGF-P3 (Graves and Cochran, 1990). Growth factors, in general, share a
number of features in common. First, they are proteins that affect cellular activity by binding
to high affinity plasma membrane receptors. Secondly, they act locally in a paracrine or
autocrine manner. Thirdly, they appear to be tightly regulated in normal cells. Fourthly, they
are multifunctional, affecting cellular events such as mitogenesis, cell migration, and
differentiation. Lastly, their activity in vivo is probably the result of the interaction of multiple
growth factors.
The original isolation and characterization of TGF-031 began in the late 1970's when
sarcoma growth factor was described (DeLarco and Todaro, 1978). DeLarco and Todaro
found that mouse 3T3 cells transformed by Moloney sarcoma virus were able to induce a
"transformed" phenotype in non-neoplastic, rat fibroblasts. This transformed phenotype was
8characterized by the loss of density-dependent growth in culture, and by the ability to grow in
soft agar (anchorage independence), an attribute observed in malignant fibroblasts but not
seen in the original rat fibroblasts. This transforming activity of the sarcoma growth factor
was reversible when it was removed from the cells. This transformation was observed in
tumor cells other than sarcomas, thus the name was changed to "transforming growth factor"
(Roberts et al., 1980). TGF-3 was subsequently identified in bone matrix, cartilage, platelets,
lymphocytes, and other tissues (Sporn et al., 1986).
TGF-03 is a 25 kDa molecule consisting of two polypeptides joined by disulfied bonds
(Roberts et al., 1983). Three distinct forms have been identified in mammals and have been
designated TGF-031, TGF-032 and TGF-033. TGF-031 and TGF-j32 can form three isoforms: a
homodimer of TGF-031, a homodimer of TGF-132, or a heterodimer TGF-031.2 (Graves and
Cochran, 1990). TGF-131 is synthesized as a large 390 amino acid residue molecule and is
processed to a 112 amino acid polypeptide. This processed dimer is linked with the remainder
of the precursor molecule, which acts as a binding protein. TGF-3 1 is secreted in latent form
and activated when the precursor fragment is dissociated, under conditions of low pH as
found in wound healing and bone remodeling environments (Graves and Cochran, 1990). In
mammals, the primary amino acid sequence for TGF-3 1 is highly conserved, and is identical in
man, pig, cow and monkey, and is different by only one residue in mice (Graves and Cochran,
1990). TGF-134 has recently been cloned from chickens (Graves and Cochran, 1990) and
represents another member of the family.
The in vitro effects of TGF-03 are varied. Depending on the cell type, TGF-P3 may
stimulate or inhibit proliferation, block a particular differentiation pathway, stimulate
extracellular matrix formation, and promote or prevent cell migration (Barnard et al., 1990).
One of the most profound effects of TGF-P3 is its promotion of extracellular matrix formation.
This occurs as a result of increased extracellular matrix protein synthesis, and inhibition of
proteinase mediated matrix degradation (Barnard et al., 1990). These important influences of
9TGF-P3 on extracellular matrix remodelling have significant implications for its role in wound
and tissue repair, bone formation and remodeling, and embryogenesis (Barnard et al., 1990;
Bernstein et al., 1991; Beck et al, 1991; Chen et al., 1992).
Rosier et al., (1989) studied the effect of TGF-P3 on chick growth plate chondrocytes.
They found that TGF-P3 significantly increased DNA synthesis, while collagen synthesis and
cellular and matrix vesicle alkaline phosphatase activity were inhibited. TGF-P3 showed
increasing mitogenicity with increasing cellular maturation in these cultures. TGF-3
production by chondrocytes was also identified and suggests a potential autocrine role for this
growth factor in regulating chondrocyte proliferation and matrix synthesis. Bonewald et al.,
(1992) added both TGF-P3 and 1,25-(OH)2D3 to MG-63 human osteosarcoma cells and found
a synergistic increase in alkaline phosphatase specific activity and collagen type I. This
combination of factors was found to induce differentiation of the osteoblast to produce a
"mature" extracellular matrix, but was unable to bring about mineralization. Pfeilschifter et
al., (1987) using ROS 17/2.8 osteosarcoma 'cells, found that TGF-P3 increased alkaline
phosphatase activity and collagen synthesis per cell. This increase in activity was seen after 24
hours and could be completely inhibited with actinomycin D or cycloheximinde. Bonewald et
al., (1990) found that TGF-P3 was able to regulate both alkaline phosphatase and
phospholipase A2 in both plasma membranes and matrix vesicles produced by this cell line.
They concluded that the ability of TGF-P to regulate enzymes associated with calcification,
suggests that mineralization, in some way, must be influenced by TGF-P.
In vivo evidence of increased extracellular matrix synthesis was found in studies where
TGF-P3 was injected subcutaneously into neonatal mice resulting in the development of
granulation tissue at the site of injection (Roberts et al., 1986). The application of TGF-P3 to
skin Wounds in rats resulted in an accelerated rate of healing as measured by wound tensile
strength (Mustoe et al., 1987).
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TGF-13 can also induce osteogenesis and chondrogenesis in the rat femur. Joyce et al.,
(1990) injected TGF-031 or 2 into the subperiosteal region of newborn rat femurs resulting in
intramembranous bone formation and chondrogenesis. They concluded that mesenchymal
precursor cells in the periosteum can be stimulated by TGF-O3 to proliferate and differentiate in
a manner similar to that occurring in embryologic bone formation and fracture healing.
The presence of TGF-O3 in bone matrix and its ability to differentially regulate the enzyme
activities of both osteoblast-like cells and chondrocytes in culture implicate this growth factor
in being an important regulator of bone and cartilage metabolism.
D. Specific Research Objectives:
The goal of this thesis is to better understand the biochemical mechanisms used by
chondrocytes in response to treatment with TGF-O3 and vitamin D3 metabolites to effect
changes in metabolism. This thesis will examine the role of PKC, tyrosine kinases, and
phospholipase C mediating the effect of TGFI3 and vitamin D3 on rat costochondral
chondrocytes in culture (Boyan et al., 1988).
The following objectives outline the course of study:
1. Conduct dose-dependence and time course experiments to determine the optimal
time and concentration of vitamin D3 metabolite and TGP-03 for both growth zone and resting
zone chondrocytes.
2. Determine the effect of pretreatment with the phospholipase C inhibitor, U73122, or
the tyrosine kinase inhibitor, genistein, on TGF-3 or vitamin D metabolite-mediated PKC
activity.
3. Perform Western Blot analysis to identify PKC isoforms in chondrocytes treated
with either vitamin D3 metabolites or TGF-3.
4. Determine the effect of actinomycin D and cycloheximide on the activation of PKC
by TGF-O3 or vitamin D3 metabolites in growth zone and resting zone chondrocytes.
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5. Determine if there is a translocational shift of PKC from the cytosol to the plasma
membrane as a result of treating growth zone and resting zone cells with TGF-P3 or vitamin D3
metabolites.
H. MATERIALS AND METHODS:
A. Materials:
Trypsin, Dulbecco's Modified Eagle's Medium (DMEM), and fetal bovine serum (FBS)
were purchased from Flow Laboratories (McLean, VA). Vitamin D3 metabolites were gifts
of Dr. Milan Uskokovic of Hoffman-LaRoche (Nutley, NJ). Recombinant human
transforming growth factor 03-1 (rhTGF-03-1) was purchased from R & D Systems, Inc.
(Minneapolis, MN). Protein kinase C assay reagents and protein kinase C inhibitor peptide
(amino acids 19-36 of pseudosubstrate region of the protein kinase C molecule) were obtained
from GIBCO-BRL (Gaithersburg, MD). Pan-specific protein kinase C antibody, MC5, was
obtained from Amersham Corp. (Arlington Heights, IL). Anti-protein kinase C alpha and beta
isoform-specific antibodies were obtained from GIBCO-BRL (Gaithersburg, MD); anti-delta
and anti-epsilon-specific isoform antibodies were a gift of Dr. Shigeo Ohno (Department of
Molecular Biology, Yokohama City University Medical School, Yokohama, Japan). The
bicinchoninic acid (BCA) protein assay reagent was obtained from Pierce Chemical Co.
(Rockford, II). Genistein, actinomycin D, cycloheximide, and rat brain PKC (E.C.2.7.1.37)
were purchased from Calbiochem (San Diego, CA). U73122 was a gift from Dr. John
Bleasdale, The Upjohn Co. (Kalamazoo, MI).
B. Chondrocyte Cultures:
The culture system has been described previously by Boyan et al., (1988). Ribcages
were removed from 125 g Sprague-Dawley rats and placed in Dulbecco's modified Eagle's
medium (DMEM). The resting zone and adjacent growth zone cartilage were dissected and
the intervening tissue removed to limit cross-contamination of cell zones, then sliced and
incubated overnight in DMEM containing antibiotics at 370 C with 5% CO 2 in air and 100%
humidity. The DMEM was replaced by two 20-minute washes in Hanks' Balanced Salt
Solution (HBSS), followed by sequential incubations in 1% trypsin for 1 hour and 0.02%
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collagenase (GIBCO Type II) for 3 hours (Suzuki et al., 1981). After enzymatic digestion,
cells were seperated from debris by filtration, collected by centrifugation at 500 x g for ten
minutes, resuspended in DMEM, and plated at a density of 10,000 cells/cm 2 for resting zone
cells or 25,000 cells/cm 2 for growth zone cells as described by Rifas, et al. (1982). Cultures
were incubated in DMEM containing 10% fetal bovine serum (FBS), 1% penicillin-
streptomycin-fungizone, and 50 iig/ml ascorbic acid (vitamin C) in an atmosphere of 5% CO 2
in air at 370 C and 100% humidity. The media were changed at 24 hours and then at 72-hour
intervals thereafter. At confluence (7-10 days), cells were subcultured using the same plating
densities and technique as those described above and allowed to return to confluence. Third
passage confluent cultures were subpassaged into either 24-well microtiter plates or T-25
flasks and grown to confluence for the experiments. In all experiments cells were subcultured
in this manner, since previous studies have demonstrated a retention of differential phenotypic
markers (Boyan et al., 1988).
C. Experimental Protocols:
For each experiment, confluent cultures of fourth passage chondrocytes were treated for
various periods of time with control or experimental DMEM containing various
concentrations of either vitamin D3 metabolite or rhTGF-031. To determine the optimal time
course, preliminary experiments were performed. Chondrocytes were incubated with the
appropriate vitamin D3 metabolite for 0, 3, 9, 30, or 90 minutes. For subsequent experiments,
growth zone cells were treated with 10-10 M - 10-7 M 1,25-(OH)2D3 or 10-9 M - 10-7 M
24,25-(OH)2D3 for up to 24 hours. Resting zone cells were treated with 10-9 M - 10-7 M
24,25-(O0t)2D3 or 10-9 M - 10-7 M 1,25-(OH) 2D3 for up to 24 hours. Chondrocytes treated
with rhTGF-031 were incubated for 0, 1.5, 4.5, 6, 9, 12, 24, 48, or 72 hours. For subsequent
experiments with rhTGF-131, growth zone and resting zone cells were treated with 0.05-5
ng/ml rhTGF-031 for up to 72 hours. Initial time-course and dose-response experiments
included rhTGF-1 1 concentrations as high as 5 ng/mi, while subsequent experiments used
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0.11 ng/ml and 0.22 ng/ml doses, which produced a sufficient dose-response effect. After
various lengths of exposure to vitamin D3 metabolite or growth factor, the cells were washed
with phosphate buffered saline (PBS), loosened from the wells with a sterile cell scraper, and
lysed in solubilization buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA, 1mM
phenylmethylsulfonylfluoride and 1% NP-40) for 30 minutes on ice. The lysates were used
for assay of PKC activity.
D. Protein Kinase C:
1. Assay. Chondrocyte lysates were incubated for 20 minutes with a lipid
preparation (7:1, v/v) containing phorbol-12-myristate-13-acetate, phosphatidlyserine and
Triton X-100 mixed micelles, which provides the necessary cofactors and conditions for
optimal activity (Bell et al., 1986). To this mixture, a high affinity myelin basic protein
peptide (MBP, 8p.M) and 32p-ATP (25 4.Ci/ml) were added to a final assay volume of 50 pl.
Following a 10-minute incubation at 300 C, samples were spotted onto phosphocellulose discs
and washed twice with 1% phosphoric acid and once with distilled water to remove
unincorporated label prior to placement in the scintillation counter. The phosphocellulose disc
strongly binds the MBP peptide substrate which becomes 32P-labeled during the protein
kinase C reaction and unincorporated 32p-ATP is washed free of the discs during the
phosphoric acid wash step.
2. Inhibitor Peptide. To verify that the kinase activity was due to authentic PKC,
and not due to other protein kinases, a specific inhibitor peptide corresponding to amino acid
residues 19-36 of the protein kinase C pseudosubstrate region, was added to the protein
kinase C reaction tubes at a final concentration of 3 p-M.
3. Western Blot. To verify that protein kinase C was present in the chondrocytes,
the following protocol was used. T-25 flasks of confluent fourth passage resting zone
chondrocytes were lysed in 2 ml of solubilization buffer for 30 minutes on ice and centrifuged
at 15,000 x g for 1 minute to remove debris. The lysates were then incubated for 1 hour with
15
20 pl of a pan-specific anti-protein kinase C IgG (Amersham Corp., Arlington Heights, IL),
followed by either a 4-hour or 16-hour incubation with 20 pl of protein A-agarose (Oncogene
Science, Inc., Uniondale, NY). The immunoprecipitated pellet was washed twice with
solubilization buffer, twice with ultrapure deionized water, and then boiled for 4 minutes in
loading buffer. Prior to electrophoresis, the sample was centrifuged for 30 seconds and the
supernatant applied to a 7.5% SDS-polyacrylamide gel (8-12 hours at 10-20 mA). Authentic
purified rat brain protein kinase C was run alongside the experimental samples to facilitate
determination of the chondrocyte protein kinase C band(s). The gels were transferred to
Immobilon-P membranes using a semi-dry electroblotter (American Bionetics, Hayward, CA)
(2.5 mA/cm for 1.5 hours). The membranes were then blocked overnight in 5% nonfat dry
milk and probed with an anti-protein kinase C primary antibody for one hour. This was
followed by horseradish peroxidase-conjugate anti-IgG secondary antibody for one hour.
Each antibody was diluted 1:500 in PBS-0.1% Tween-20 (PBST) and the membranes were
washed three times with PBST before and after addition of the secondary antibody.
Visualization of the protein kinase C bands was achieved using a luminol-based enhanced
chemiluminescence (ECL) kit (Amersham Corp., Arlington Heights, IL) for one minute. The
membrane was then exposed to Kodak XAR-5 film and the film developed.
4. Immunoprecipitation. To establish which of the protein kinase C isoforms is
present in the chondrocytes, the following protocol was used. T-25 flasks of confluent fourth
passage resting zone chondrocytes, pretreated 24 hours with control DMEM plus 10% FBS
with or without rhTGF-131, were lysed in 3ml of solubilization buffer for one hour on ice.
Lysates were then spun for one minute at 15,000 x g to remove debris and aliquots removed
for protein analysis before dividing samples into six equivalent volumes. These samples were
then incubated with 10!.l of PBS or 10pl of 1:2000 dilutions of anti-protein kinase C isoform
specific antibodies (anti-a, P3, 5, or e) or nonspecific goat anti-mouse immunoglobulin on ice
for one hour. Each sample then received 10[dtl of protein A-agarose, followed by a four-hour
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incubation at 40 C with agitation to precipitate the protein kinase C-antibody complexes.
Protein kinase C activity remaining in the cleared lysates was assayed as described above.
E. Translocation Experiments:
For PKC translocation experiments, fourth passage growth zone or resting zone cells were
cultured and treated with control DMEM or DMEM containing 0.11 or 0.22ng/ml rhTGF-I31
for 12 hours. In addition, growth zone chondrocytes were treated with control media or 10-9-
10-8M 1,25-(OH) 2D3 for nine minutes, and resting zone chondrocytes were treated with
control media or 10-8 to 10-7 M 24,25-(OH) 2D3 for 90 minutes. Membrane and cytosol
fractions were isolated using a modification of a procedure used to investigate protein kinase
C translocation in osteosarcoma cells (Abou-Samra et al., 1989). The cells were pelleted by
centrifugation at 100 x g for ten minutes, resuspended in ice-cold homogenization buffer
containing 20mM Tris-HCl, pH 7.4, 2mM EDTA, 0.5mM phenylmethylsulfonylfluoride plus
1% NP-40, and homogenized on ice in a Dounce homogenizer (30 strokes). The homogenate
was centrifuged at 100,000 x g for 45 minutes, and the pellet containing the membranes was
resuspended in homogenization buffer plus 1% NP-40. Protein concentration and protein
kinase C activity were assayed in the cytosol and membrane fractions from control and either
vitamin D 3 or rhTGF-13 1-treated chondrocyte cultures.
F. Tyrosine Kinase and Phospholipase C:
In order to determine whether tyrosine kinase or phospholipase C was involved in the
mechanism of protein kinase C activation, growth zone or resting zone chondrocyte cultures
were pretreated with 0.1 - 10 ýtM of either the tyrosine kinase inhibitor, genistein, or the
phospholipase C inhibitor, U73122. Cultures were pretreated with control media or inhibitors
for 2 hours at which time the media were changed to control or experimental media containing
vitamin D 3 metabolite or rhTGF-3 1. Protein concentration and protein kinase C activity were
measured. Cell viability was determined using trypan blue dye exclusion for chondrocyte
cultures exposed to media containing 10 ptM genistein or 10 ptM U73122 for 72 hours.
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G. Transcription and Translation:
To examine the involvement of genomic mechanisms in protein kinase C activation, the
chondrocyte cultures were treated with vitamin D3 metabolites or rhTGF-031 in the presence
of the transcription inhibitor, actinomycin D, or the translation inhibitor, cycloheximide.
Growth zone chondrocytes were incubated with control or 10-9 - 10-8 M 1,25-(OH) 2D3 and
0.01 or 0.1 mM actinomycin D or cycloheximide for 9 minutes. Resting zone chondrocytes
were incubated with control or 10-8 M - 10-7 M 24,25-(OH) 2 D3 and 0.01 or 0.1 mM
actinomycin D or cycloheximide for one hour. Both growth zone and resting zone
chondrocytes were incubated with control, 0.11, 0.22, or 10 ng/ml rhTGF-031 and 0.01 or 0.1
mM actinomycin D or cycloheximide for 12 hours. Following treatment with the inhibitors,
the cells were washed with PBS and assayed for protein kinase C activity.
H. Protein Determination:
The protein content of each experimental sample was determined using the Macro BCA
Protein Assay Reagent (Pierce Chemical Co., Rockford, IL). This was accomplished so that
enzyme specific activities could be calculated for each sample. This assay system is highly
sensitive for the determination of protein concentration in dilute solution. Bicinchoninic acid
(BCA), in the form of a water-soluble salt, is a sensitive reagent for copper. The Macro BCA
Protein Assay Reagent combines the biuret reaction (Protein reacting with Cu2 +) with BCA.
A purple product is formed by the interaction of two molecules of BCA with one cuprous ion
(Cul+), and exhibits a strong absorbance at 562 nm. This absorbance was measured
spectrophotometrically with an automatic densitometer (BioRad, Inc., Richmond, CA).
I. Statistical Analysis:
Data on the regulation of protein kinase C activity by vitamin D3 metabolites or rhTGF-03
1 are expressed as the mean pMol phosphate transferred/gig protein/minute + standard error
of the mean (SEM) of six cultures. Observations were validated by independent experimental
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replicates (minimum of two). Significance between treatment and controls was determined by
the Bonferroni's t-test using P<0.05 confidence limits.
HI. RESULTS
A. Vitamin D Metabolites:
1. Time-Course. When growth zone chondrocytes were incubated from 0-90
minutes with 10-10 - 10-8 M 1,25-(OH) 2D3, there was a stimulation of PKC activity that
occurred as early as 3 minutes after addition of hormone (Table 1) and was significant at 10-8
M. Subsequent experiments, over longer periods of time, showed that peak stimulation
occurred at 9 minutes and was sustained for 90 minutes (Figure 1A). In another experiment,
this profile was reproducible, and no subsequent increase in activity was observed at 6, 12, or
24 hours following 1,25-(OH) 2D3 exposure. 24,25-(OH) 2D3 did not activate PKC in growth
zone chondrocyte cultures at any of the times and concentrations tested (Figure 1B), nor at 6,
12, or 24 hours.
1,25-(OH) 2D3 did not activate PKC in resting zone cell cultures at any dose or time
examined (Figure 2A). Resting zone cell cultures did exhibit increased PKC activation in
response to stimulation by 24,25-(OH)2D3. A significant increase in activity began between 9
and 30 minutes after addition of hormone and reached a maximum at 90 minutes. High levels
of activity were sustained for an additional 180 minutes after reaching their peak levels. The
effect of hormone was still significant at 4.5 hours after addition in cultures exposed to 10- -
10-7 M 24,25-(OH) 2D3 (Figure 2B).
2. Specificity to PKC. The protein kinase activity regulated by vitamin D3
metabolites in chondrocytes was confirmed to be PKC by addition of a specific competitive
inhibitor peptide (Table 2). The PKC inhibitor at a final concentration of 3 IIM reduced 1,25-
(OH)2D3 -stimulated PKC activity in growth zone cell lysates by 95.6%. 24,25-(OH) 2D3-
stimulated activity in resting zone cell lysates was reduced by 85.9%.
3. Western Blot. When Western blots were probed using an anti-rat PKC antibody
which recognizes all isoforms of the enzyme (Figure 3), the major immunoreactive protein
19
20
Table 1. 1,25-(OH) 2 D3 -DEPENDENT EFFECT ON PROTEIN KINASE C
SPECIFIC ACTIVITY OF GROWTH ZONE CHONDROCYTES.
1,25-(OH) 2 D3  pMol P0 4/ug Protein/ Minute
0 0.129+0.018
10" 10 M 0.081 + 0.009
10"9 M 0.124 + 0.023
10- 8 M 0.781 + 0.024 *
At confluence, growth zone chondrocytes were incubated with control medium
(vehicle only) or with medium containing 1,25-(OH)2D3 for 3 minutes.
Values are mean + SEM for 6 cultures. Data are from a single experiment and
were validated in a replicated experiment. *p < 0.05, treated vs. control.
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Figure 1A. PROTEIN KINASE C SPECIFIC ACTIVITY OF GROWTH ZONE
CHONDROCYTES AFTER TREATMENT WITH 1,25-(OH)2D3 FOR VARIOUS
PERIODS OF TIME. Confluent, fourth passage growth zone chondrocytes were treated
for various periods of time with DMEM + 10% FBS and various concentrations of 1,25-
(OH)2D3. Each point represents the mean + SEM of protein kinase C specific activity for 6
cultures. Data are from one of two replicate experiments. *p<0.05, treatment vs control.
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Figure lB. PROTEIN KINASE C SPECIFIC ACTIVITY OF GROWTH ZONE
CHONDROCYTES AFTER TREATMENT WITH 24,25-(OH)2D3 FOR VARIOUS
PERIODS OF TIME. Confluent, fourth passage growth zone chondrocytes were treated for
various periods of time with DMEM + 10% FBS and various concentrations of 24,25-
(OH)2D3. Each point represents the mean + SEM of protein kinase C specific activity for 6
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Figure 2A. PROTEIN KINASE C SPECIFIC ACTIVITY OF RESTING ZONE
CHONDROCYTES AFTER TREATMENT WITH 1,25-(OH)2D3 FOR VARIOUS
PERIODS OF TIME. Confluent, fourth passage resting zone chondrocytes were treated for
various periods of time with DMEM + 10% FBS and various concentrations of 1,25-
(OH)2D3. Each point represents the mean + SEM of protein kinase C specific activity for 6
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Figure 2B. PROTEIN KINASE C SPECIFIC ACTIVITY OF RESTING ZONE
CHONDROCYTES AFTER TREATMENT WITH 24,25-(OH)2D3 FOR VARIOUS
PERIODS OF TIME. Confluent, fourth passage resting zone chondrocytes were treated
for various periods of time with DMEM + 10% FBS and various concentrations of 24,25-
(OH)2D3. Each point represents the mean + SEM of protein kinase C specific activity for 6
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Table 2. EFFECT OF PROTEIN KINASE C INHIBITOR PEPTIDE ON
PROTEIN KINASE C SPECIFIC ACTIVITY OF GROWTH ZONE
(GC) AND RESTING ZONE (RC) CHONDROCYTES.
Protein Kinase C Specific Activity
pMol PO4/pg Protein/Minute
Treatment GC RC
Control 0.65 +0.01 0.87 + 0.01
Control + 0.83 +0.01 0.83 + 0.01
inhibitor (3 jtM)
1,25-(OH)2D3 (10-8 M) 8.92 + 0.01 N.D
1,25-(OH)2D3 (10- 8M) + 0.40 + 0.0 1 N.D
inhibitor (3 jtM)
24,25-(OH)2D3 (10" 8M) N.D. 10.89 + 0.02
24,25-(OH)2D3 (10-8 M) + N.D. 1.53 + 0.02*
inhibitor (3 jtM)
Values represent the mean + SEM of six cultures. Data are from a single experiment. The
observations were validated in 2 replicate experiments. *p < 0.05, hormone + 3 uM inhibitor
vs. hormone alone. N.D., not done.
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Figure 3. WESTERN BLOT ANALYSIS OF PROTEIN KINASE C (PKC) PROTEIN
IN RAT COSTOCHONDRAL CHONDROCYTE CELL LYSATES. Fourth passage
resting zone (left panel) and growth zone (right panel) chondrocytes were cultured to
confluence in T-25 flasks, lysed in solubilization buffer, immunoprecipitated with pan-specific
anti-rat protein kinase C antibody, separated on a 7.5% SDS-PAGE, transferred to
Immobilon-P (1 hour at 320 mA), probed with anti-protein kinase C IgG and visualized with a
luminol-based detection system,(ECL, Amersham Corp.). Migration of the major chondrocyte
protein kinase C (first band) was identical to purified rat brain protein kinase C standard
(second band). Molecular weight region 97-66 kD is shown.





produced by resting zone and growth zone cells had an apparent molecular weight of 78 kDa.
When longer exposure times were used, numerous additional bands were detected throughout
the Western blot. These were presumed to be due to aggregation, degradation, or nonspecific
binding, since they did not co-migrate with authentic PKC.
4. Translocation Experiments. Upon stimulation with vitamin D3 metabolites, PKC
appears to translocate from the cytosol to the membrane (Table 3). After treatment of growth
zone chondrocytes with 10-8 M 1,25-(OH) 2D3 for 9 minutes, the amount of PKC specific
activity in the cytosol increased 4.5 fold, whereas the enzyme specific activity in the membrane
increased 31-fold. Similarly, after resting zone chondrocytes were exposed to 24,25-(OH) 2D3
for 90 minutes, PKC specific activity in the cytosol increased 6.8-fold, while specific activity
in the membranes increased 23.7-fold.
5. Tyrosine Kinase and Phospholipase C. Pretreatment with U73122 (phospholipase
C inhibitor) had no effect on basal PKC specific activity levels in growth zone (Figure 4A) or
resting zone (Figure 4B) cell cultures. U73122 reduced 1,25-(OH) 2D3-stimulated PKC
specific activity in growth zone cell cultures in a dose-dependent manner (Figure 4A). The
inhibitory effect of U73122 was significant at concentrations of 0.1, 1, and 10 pgM, reducing
PKC specific activity 23%, 43%, and 78%, respectively. The phospholipase C inhibitor had
no effect on 24,25-(OH) 2D3-stimulated PKC specific activity in resting zone cell cultures at
any concentration or time point examined (Figure 4B). When treated with the highest
concentration of U73122 (10 pM), chondrocyte cultures displayed at least 98% viability,
indicating that the compound was well tolerated by the cells, and the reduction in PKC
specific activity was not a result of cytotoxicity.
Unlike the inhibition observed for U73122, genistein (tyrosine kinase inhibitor) had no
significant effect on vitamin D3-stimulated PKC specific activity in either growth zone or
resting zone cell cultures (data not shown). Cell viability following genistein treatment was
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Table 3. PROTEIN KINASE C SPECIFIC ACTIVITY IN CHONDROCYTE
CYTOSOL AND MEMBRANE FRACTIONS AFTER TREATMENT WITH
VITAMIN D METABOLITES.
Growth Zone Cells Resting Zone Cells
Treatment Cytosol Membrane Cytosol Membrane
Control 2.55+0.04 0.66+0.02 3.43+0.07 0.54+0.02
1,25-(OH)2D3 11.56+0.69 20.44+0.46 N.D. N.D.(10- 8M)
24,25-(OH)2D3 N.D. N.D. 23.43+0.31 12.77+0.26(10- 8M)
Values represent the mean + SEM for protein kinase C specific activity (pMol P0 4/pg
protein/min). Data are from a single experiment with six determinations for each condition.
N.D., not done.
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Figure 4A. EFFECT OF U73122 ON PROTEIN KINASE C SPECIFIC ACTIVITY IN
GROWTH ZONE CHONDROCYTES INCUBATED WITH 1,25-(OH)2D3. Confluent,
fourth passage growth zone chondrocytes were treated for two hours with various
concentrations of U73122 followed by fresh media + 1,25-(OH)2D3 for 9 minutes. Each
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Figure 4B. EFFECT OF U73122 ON PROTEIN KINASE C SPECIFIC ACTIVITY IN
RESTING ZONE CHONDROCYTES INCUBATED WITH 24,25-(OH)2D3. Confluent,
fourth passage resting zone chondrocytes were treated for two hours with various
concentrations of U73122 followed by fresh media + 24,25-(OH)2D3 for 90 minutes. Each
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never less than 96%, indicating that the concentrations used were not deleterious to the
chondrocytes.
6. Transcription and Translation. The transcription inhibitor, actinomycin D, had no
effect upon 1,25-(OH) 2D3 -stimulated PKC specific activity in growth zone cell cultures
(Figure 5A). Similarly, the translation inhibitor, cycloheximide, did not alter 1,25-(OH) 2D3-
stimulated PKC specific activity in growth zone cell cultures at the concentrations tested
(Figure 5B).
In contrast, actinomycin D and cycloheximide both produced dose-dependent inhibition
of 24,25-(OH) 2D3-stimulated PKC specific activity in resting zone chondrocytes. PKC
specific activity was reduced 18.1% by 0.01 mM actinomycin D and 33.4% by 0.1 mM
actinomycin D in resting zone cells treated with 10-7 M 24,25-(OH) 2D3 (Figure 6A).
Similarly, PKC specific activity was reduced 28.2% by 0.01 mM cycloheximide and 46.7% by
0.1 mM cycloheximide in resting zone cells treated with 10-7 M 24,25-(OH) 2D3 (Figure 6B).
In resting zone cells incubated with 10-8 M 24,25-(OH) 2D3, PKC specific activity was
inhibited only at the highest concentration of actinomycin D or cycloheximide.
B. rhTGF-51:
1. Time-Course Experiments. rhTGF-j31 stimulated PKC specific activity in both
growth zone and resting zone chondrocyte cultures, although the time course of response was
different. In growth zone chondrocytes, stimulation of PKC specific activity by rhTGF-PI
was found at 12 and 24 hours, with significant increases observed for all three concentrations
at 12 hours (Figure 7A). By 24 hours, only the highest concentration of rhTGF-131 effected a
significant increase in the specific activity of PKC. By 48 hours, the activity was reduced to
control levels. For resting zone chondrocytes, a significant increase in PKC specific activity
was observed at nine hours after growth factor addition in cultures treated with both 0.5 and
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Figure 5A. EFFECT OF ACTINOMYCIN D ON PROTEIN KINASE C SPECIFIC
ACTIVITY IN GROWTH ZONE CHONDROCYTES INCUBATED WITH 1,25-
(OH)2D3. Confluent, fourth passage growth zone chondrocytes were treated with various
concentrations of 1,25-(OH)2D3 for 9 minutes in the absence or presence of actinomycin D.









Figure 5B. EFFECT OF CYCLOHEXIMIDE ON PROTEIN KINASE C SPECIFIC
ACTIVITY IN GROWTH ZONE CHONDROCYTES INCUBATED WITH 1,25-
(OH)2D3. Confluent, fourth passage growth zone chondrocytes were treated with various
concentrations of 1,25-(OH)2D3 for 9 minutes in the absence or presence of cycloheximide.















Figure 6A. EFFECT OF ACTINOMYCIN D ON PROTEIN KINASE C SPECIFIC
ACTIVITY IN RESTING ZONE CHONDROCYTES INCUBATED WITH 24,25-
(OH)2D3. Confluent, fourth passage resting zone chondrocytes were treated with various
concentrations of 24,25-(OH)2D3 for 90 minutes in the absence or presence of actinomycin D.












Figure 6B. EFFECT OF CYCLOHEXIMIDE ON PROTEIN KINASE C SPECIFIC
ACTIVITY IN RESTING ZONE CHONDROCYTES INCUBATED WITH 24,25-
(OH)2D3. Confluent, fourth passage resting zone chondrocytes were treated with various
concentrations of 24,25-(OH)2D3 for 90 minutes in the absence or presenc.e of cycloheximide.












Figure 7A. STIMULATION OF PROTEIN KINASE C SPECIFIC ACTIVITY IN
GROWTH ZONE CHONDROCYTES AFTER TREATMENT WITH rhTGF-J31.
Confluent, fourth passage growth zone chondrocytes were treated for various incubation
times with 0-5 ng/ml recombinant human rhTGF-J31 in DMEM + 10% FBS. Each point
represents the mean + SEM of protein kinase C specific activity for six cultures. Data are
from one of three replicate experiments. *P<0.05, treatment vs. control.
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5ng/ml rhTGF-131. Peak stimulation was observed at 12 hours and continued for 24 hours
before returning to control levels at 48 hours (Figure 7B). These time courses of activation
were reproducible in at least three independent experiments for both growth zone and resting
zone chondrocyte cultures. Occasionally, activation was observed as early as six hours
following exposure to rhTGF-131 in resting zone cells; however, peak stimulation was always
seen at the 12-hour time point.
2. Specificity to PKC. We verified that kinase regulation in chondrocytes by TGF-13
1 was indeed PKC and not catalyzed by other cellular kinases. A PKC inhibitor peptide, at a
final concentration of 3WjiM, reduced rhTGF-3 13-stimulated PKC specific activity in growth
zone cell lysates by 87.3%, and by 88.3% in resting zone cell lysates, with no discernible
effect upon basal PKC specific activity (Table 4).
3. Western Blot. Detection of PKC protein in resting zone chondrocyte cultures by
Western blot analysis using a pan-specific antibody showed a single major immunoreactive
species in the molecular weight range of 77-83 kDa that comigrated with a PKC standard
purified from rat brain (Figure 8). The PKC bands observed in immunoprecipitates from
control and rhTGF-131-treated resting zone chondrocyte cultures have a calculated molecular
weight of 78kDa. The blot shows that, while the intensity of additional lower molecular
weight bands is less in the rhTGF-131-treated sample lane, the intensity of the PKC band is
greater.
4. Immunoprecipitation. Only anti-PKC alpha reduced activity in resting zone
chondrocyte lysates, while specific antibodies to the 03, 8, and 6 isoforms of PKC had no effect
(Table 5). Treatment with non-specific IgG reduced PKC specific activity by 19.6% in
control lysates and by 27.9% in lysates from rhTGF-3 1-treated cells compared to lysates in the
absence of non-specific IgG. Anti-J3, -8 and -e antibodies produced similar results, reducing
PKC specific activity by an average of 21.9% for lysates from control cells
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Figure 7B. STIMULATION OF PROTEIN KINASE C SPECIFIC ACTIVITY IN
RESTING ZONE CHONDROCYTES AFTER TREATMENT WITH rhTGF-031.
Confluent, fourth passage resting zone chondrocytes were treated for various incubation times
with 0-5 ng/ml recombinant human rhTGF-f31 in DMEM + 10% FBS. Each point represents
the mean + SEM of protein kinase C specific activity for six cultures. Data are from one of
five replicate experiments. *P<0.05, treatment vs. control.
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Table 4. EFFECT OF PROTEIN KINASE C INHIBITOR PEPTIDE ON rhTGF-J31-
INDUCED PROTEIN KINASE C SPECIFIC ACTIVITY IN
COSTOCHONDRAL CHONDROCYTES.
Protein Kinase C Specific Activity
pMol P0 4/1ig Protein/ Minute
Treatment GC RC
Control 6.5 + 0.1 8.7 + 0.1
Control + Inhibitor 8.3 + 0.1 8.3 + 0.1
TGFO 99.6 + 0.1 116.5 + 0.3
TGF3 + Inhibitor 11.1 +0.1* 14.8 +0.3*
Protein kinase C specific activity (pMol P0 4/jtg protein/min) is expressed as the mean + SEM
of six cultures treated for 12 hours with control media or 5ng/ml rhTGF-131 (TGFI3). Inhibitor
peptide was added at the time of assay at a concentration of 3pM. Data are from a single
experiment and the observations were validated in two replicate experiments. GC: growth
zone chondrocytes; RC: resting zone chondrocytes; *p < 0.05, TGF.3 + inhibitor vs. TGFO3
alone.
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Figure 8. WESTERN BLOT ANALYSIS OF PROTEIN KINASE C PROTEIN IN
RAT COSTOCHONDRAL CHONDROCYTE CELL LYSATES TREATED WITH
CONTROL OR TGFO3. Fourth passage resting zone chondrocytes were cultured to
confluence and treated with control DMEM + FBS (lanes 2,3) or 5 ng/ml rhTGF-031 (lane
4,5) for 24 hours, lysed in solubilization buffer, immunoprecipitated with pan-specific protein
kinase C antibody (lanes 2 and 4) or nonspecific goat anti-mouse IgG (lanes 3 and 5),
separated on a 7.5% SDS-PAGE, transferred to Immobilon P (1 hr at 320 mA), probed with
anti-protein kinase C IgG and visualized with a luminol-based detection system (ECL,
Amersham Corp.). Migration of the major chondrocyte protein kinase C was identical to
purified rat brain protein kinase C standard (lane 6). Prestained molecular weight markers
shown in lane 1.
Mr (kD) Control TGF-f3 PKC
180-
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Table 5. EFFECT OF ISOFORM-SPECIFIC ANTIBODIES ON PROTEIN KINASE




Non-specific IgG 80.4 + 5.9 72.1 + 2.8
Alpha 34.3 ± 0.6* 7.8 +0.2*
Beta 78.3 + 2.4 66.6 + 1.2
Delta 81.5+1.4 76.3+1.7
Epsilon 74.6 + 8.3 75.2 + 0.6
Protein kinase C specific activity is expressed as % control of activity remaining in untreated
and 12-hour rhTGF-01 1-treated resting zone chondrocyte lysates prior to and following
treatment with anti-protein kinase C isoform-specific antibodies. Values represent the mean +
SEM for six cultures. *P<0.05, specific antibody vs. nonspecific IgG.
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and 27.3% from TGFO3-treated cells. Anti-ct antibody, however, reduced PKC specific
activity by 65.7% in lysates of controls and by 92.2% for TGFO3-treated cells. PKC specific
activity in the rhTGF-0 1-treated chondrocytes was decreased to a greater extent than in the
control cells.
5. Translocation. rhTGF-3 1 does not appear to promote substantial
translocation of PKC to the cell membrane at the time points and concentrations examined
(Table 6). The level of PKC specific activity in membrane fractions isolated from growth
zone chondrocyte cultures exposed to 0.1 lng/ml rhTGF-31 for 12 hours was 2.3-fold greater
than control membranes, while those exposed to 0.22ng/ml were only 1.7-fold greater.
Following a 12-hour exposure to 0.1lng/ml rhTGF-031, there was a 3.0-fold increase in
activity in resting zone cell membranes, while 0.22ng/ml only produced a 1.8-fold increase.
In contrast, dose dependent increases in the cytosolic enzyme activity were observed. Growth
zone cells exhibited a 1.9-fold increase when incubated with 0.11 ng/ml rhTGF-131 and a 4.2-
fold increase when incubated with 0.22 ng/ml rhTGF-031. Resting zone cells exhibited a 3.4-
fold increase when incubated with 0.11 ng/ml rhTGF-3 1 and a 6.1-fold increase at 0.22 ng/ml
rhTGF-31. Unlike cells treated with rhTGF-031, chondrocytes treated with their specific
vitamin D metabolite showed translocation of PKC from cytosol to the membrane.
6. Tyrosine Kinase and Phospholipase C. The phospholipase C inhibitor
U73 122 (0. 1-10jItM) had no significant effect on basal PKC specific activity levels in confluent
growth zone or resting zone chondrocytes treated with control DMEM + 10% FBS for 1.5,
4.5, 6, 12, 24, 48 or 72 hours (data not shown). In growth zone chondrocytes, U73122 had
no dramatic affect on the TGF-03-induced rise in PKC specific activity observed at 12 or 24
hours following growth factor and phospholipase C inhibitor addition (Figure 9A). However,
slight, but significant, increases in activity were found 12 hours after addition of rhTGF-031 to
growth zone chondrocytes cultured in the presence of 0.1-10gM U73122. This increase
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Table 6. TRANSLOCATION OF PROTEIN KINASE C SPECIFIC ACTIVITY
IN CHONDROCYTE CULTURES TREATED WITH rhTGF-01.
Growth Zone Cells Resting Zone Cells
Treatment Membrane Cytosol Membrane Cyoso1l
Control/PBS 0.240 + 0.008 0.706 + 0.001 0.229 + 0.008 0.818 + 0.011
0.11ng/ml TGFO3 0.562 + 0.0110 1.369 +0.016* 0.690 + 0.019# 2.784 + 0.028*
0.22ng/ml TGFO3 0.406 + 0.013 2.947 + 0.020* 0.401 + 0.010 4.955 + 0.068*
lOng/ml TGFO3 0.312 + 0.003 5.247 + 0.019* 0.391 + 0.011 13.291 + 0.097*
Values represent the mean + SEM protein kinase C specific activity (pMol P0 4/gg
protein/min) of six cultures. Growth zone and resting zone chondrocytes were treated with
rhTGF-p3l (TGFO3) for 12 hours. Control media contained phosphate buffered saline (PBS)
vehicle. Data are from one of two replicate experiments. *P<0.01, treatment vs. control;
"#P<0.05, treatment vs. control; N.D., not done.
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Figure 9A. EFFECT OF U73122 ON PROTEIN KINASE C SPECIFIC ACTIVITY IN
GROWTH ZONE CHONDROCYTES TREATED WITH rhTGF-01. Confluent fourth
passage chondrocytes were pretreated for 2 hours with 0-10 pM U73122, followed by fresh
medium containing 5 ng/ml rhTGF-031 and 0-10 pM U73122 for various times. Each point
represents the mean + SEM of protein kinase C specific activity for six cultures. Data are
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appeared to be dose-dependent at 0.1 and 1 jiM U73122, but no further increase was seen at
lOM. For rhTGF-13 1-treated resting zone cells, U73122 had no significant affect on PKC
specific activity (Figure 9B). Unlike the slight enhancement seen in growth zone
chondrocytes under similar conditions, no significant alteration of PKC specific activity was
observed at the 6, 12, or 24 hour time points.
The tyrosine kinase inhibitor, genistein (0.1-10 pn), had no effect on basal PKC
specific activity in growth zone or resting zone chondrocytes (data not shown). In growth
zone chondrocytes, genistein had no effect on the rhTGF- 1I-mediated increase in PKC
specific activity at any of the time points examined (Figure 10A). In resting zone cells,
genistein did not affect the TGFO3 effect on PKC specific activity, but produced a small, but
significant, increase at 12 hours for the 1O0iM dose (Figure lOB).
7. Transcription and Translation. Actinomycin D produced a dose-dependent
inhibition of rhTGF-3 1 -stimulated PKC specific activity in growth zone chondrocytes at 12
hours (Figure 11A). In growth zone cultures treated with 0.11 ng/ml rhTGF-031, the PKC
specific activity was reduced 31.9% and 67.0% by 0.01 mM and 0.1 mM actinomycin D,
respectively. In growth zone cultures treated with 0.22 ng/ml and 10 ng/ml rhTGF-031, the
PKC specific activity was similarly reduced. In resting zone cultures treated with 0.11 ng/ml
rhTGF-43, the PKC specific activity was reduced by 41.6% and 71% by 0.01 mM and 0.1 mM
-actinomycin D, respectively (Figure 1 IB). In resting zone cultures treated with 0.22 ng/ml
and 10 ng/ml rhTGF-03, the PKC specific activity was similarly reduced.
Cycloheximide also produced dose-dependent inhibition of rhTGF-13 1-stimulated PKC
specific activity in growth zone chondrocytes at 12 hours (Figure 12A). In growth zone
cultures treated with 0.11 ng/ml rhTGF-031, the PKC specific activity was reduced 42.7% and
73.3% by 0.01 mM and 0.1 mM cycloheximide, respectively. In growth zone cultures treated
with 0.22 ng/ml and 10 ng/ml rhTGF-031, the PKC specific activity was similarly, reduced. In
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Figure 9B. EFFECT OF U73122 ON PROTEIN KINASE C SPECIFIC ACTIVITY IN
RESTING ZONE CHONDROCYTES TREATED WITH rhTGF-01. Confluent fourth
passage chondrocytes were pretreated for 2 hours with 0-10 pM U73122, followed by fresh
medium containing 5 ng/ml rhTGF-31 and 0-10 tiM U73 122 for various times. Each point
represents the mean + SEM of protein kinase C specific activity for six cultures. Data are
from one of two replicate experiments. *P<0.05, treatment vs. control.
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Figure 10A. EFFECT OF GENISTEIN ON PROTEIN KINASE C SPECIFIC
ACTIVITY IN GROWTH ZONE CHONDROCYTES TREATED WITH rhTGF-1.
Confluent fourth passage growth zone chondrocytes were pretreated for 2 hours with 0-10
M genistein, followed by fresh medium containing 5 nglml rhTGF-031 and 0-10 4M genistein
for various times. Each point represents the mean + SEM of protein kinase C specific activity
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Figure 10B. EFFECT OF GENISTEIN ON PROTEIN KINASE C SPECIFIC
ACTIVITY IN RESTING ZONE CHONDROCYTES TREATED WITH rhTGF-1.
Confluent fourth passage resting zone chondrocytes were pretreated for 2 hours with 0-10 p.
M genistein, followed by fresh medium contaning 5 ng/ml rhTGF-031 and 0-10 gM genistein
for various times. Each point represents the mean + SEM of protein kinase C specific activity
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Figure 11A. EFFECT OF ACTINOMYCIN D ON PROTEIN KINASE C SPECIFIC
ACTIVITY IN GROWTH ZONE CHONDROCYTES TREATED WITH rhTGF-f31.
Confluent fourth passage cultures were treated for 12 hours with various concentrations of
actinomycin D with or without 0.11 nglml, 0.22 ng/ml, or 10 ng/ml rhTGF-031. Data shown
are the mean + SEM for 6 cultures. *p<0.05. To ensure validity, experiments were repeated a
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Figure 11B. EFFECT OF ACTINOMYCIN D ON PROTEIN KINASE C SPECIFIC
ACTIVITY IN RESTING ZONE CHONDROCYTES TREATED WITH rhTGF-031.
Confluent fourth passage cultures were treated for 12 hours with various concentrations of
actinomycin D with or without 0.11 ng/ml, 0.22 ng/ml, or 10 ng/ml rhTGF-P31. Data shown
are the mean + SEM for 6 cultures. *p<0.05. To ensure validity, experiments were repeated a
minimum of 3 times.
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Figure 12A. EFFECT OF CYCLOHEXIMIDE ON PROTEIN KINASE C SPECIFIC
ACTIVITY IN GROWTH ZONE CHONDROCYTES TREATED WITH rhTGF-31.
Confluent fourth passage cultures were treated for 12 hours with various concentrations of
cycloheximide with or without 0.11 ng/ml, 0.22 ng/ml, or 10 ng/ml rhTGF031 . Data shown
are the mean + SEM for 6 cultures. *p<0.05. To ensure validity, experiments were repeated a
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resting zone cultures treated with 0.11 ng/ml rhTGF-131, the PKC specific activity was
reduced 35.9% and 67.7% by 0.01 mM cycloheximide and 0.1 mM cycloheximide,
respectively (Figure 12B). In resting zone cultures treated with 0.22 ng/ml and 10 ng/ml
rhTGF-131, the PKC specific activity was similarly reduced.
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Figure 12B. EFFECT OF CYCLOHEXIMIDE ON PROTEIN KINASE C SPECIFIC
ACTIVITY IN RESTING ZONE CHONDROCYTES TREATED WITH rhTGF-131.
Confluent fourth passage cultures were treated for 12 hours with various concentrations of
cycloheximide with or without 0.11 ng/ml, 0.22 ng/ml, or 10 ng/ml rhTGFI3 1 . Data shown
are the mean + SEM for 6 cultures. *p<0.05. To ensure validity, experiments were repeated a

















Protein kinase C specific activity is elevated in rat costochondral chondrocytes
incubated with vitamin D3 metabolites; however, the characteristics are distinct with respect
to the factor used or the type of cell. Response to vitamin D3 metabolites is dependent upon
cell maturation, with growth zone and resting zone cultures displaying differential sensitivity
and response time to 1,25-(OH)2 D3 and 24,25-(OH) 2D3 , respectively.
Specifically, these studies have revealed a rapid increase in PKC specific activity in
1,25-(OH) 2D3 -treated growth zone chondrocytes and a relatively slower increase in 24,25-
(OH) 2D3-treated resting zone chondrocytes. The translocation experiment demonstrated that
exposure to 1,25-(OH) 2 D3 elicited an increase in membrane-bound PKC specific activity in
growth zone cells, and exposure to 24,25-(OH) 2 D3 produced an increase in membrane-bound
PKC specific activity in resting zone cells. In many cell types, activation of protein kinase C
by hormones or growth factors is associated with rapid translocation of protein kinase C from
the cytosol to membrane components (Abou-Samra, et al., 1989, Hirota et al., 1985, Ohno et
al., 1991). 24,25-(OH) 2 D3 had no effect on PKC specific activity in growth zone cells, and
1,25-(OH) 2D3 had no effect on PKC specific activity in resting zone cells. The cell specificity
of the results supports the concept that 1,25-(OH) 2D3 targets growth zone cells, whereas
24,25-(OH) 2D3 targets resting zone cells.
The type of protein kinase that was stimulated by the vitamin D metabolites was the
Ca+2/phospholipid-dependent enzyme, as demonstrated by the inhibitor studies discussed
below. This indicates that changes in phospholipid metabolism and Ca flux are involved.
Previous studies have shown that 1,25-(OH) 2D3 and 24,25-(OH) 2D3 regulate arachidonic
acid incorporation and release, as well as 45Ca flux (Langston, et al., 1990, Schwartz, et al.,
1990, Swain et al., 1992). Furthermore, effects of these metabolites on phospholipase A2
activity (Schwartz et al., 1988) and membrane fluidity (Swain et al., 1993) are directly on the
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membrane and therefore nongenomic. Thus, it is likely that the vitamin D3 metabolite effects
on protein kinase C include nongenomic mechanisms as well.
To investigate the precise mechanisms of signal transduction utilized by the vitamin D3
metabolites, the potential involvement of phospholipase C and tyrosine kinases were assessed.
The aminosteroid compound U73122 has been shown to specifically inhibit phospholipase C
and to have no effect on phospholipase A2 , by interacting directly with the phospholipase C
enzyme itself (Bleasdale et al., 1989), making it a useful reagent for determination of
phospholipase C-mediated events. U73122 reduced 1,25-(OH)2D3-stimulated PKC specific
activity in growth zone cell cultures in a dose-dependent manner, yet had no effect on the
24,25-(OH) 2D3 response. This result suggests that signaling by 1,25-(OI-t)2D3 is
phospholipase C dependent, while 24,25-(OH) 2D3 may activate protein kinase C by an
alternative pathway.
The failure of genistein to inhibit the chondrocyte protein kinase C response to 1,25-
(OH) 2D 3 or 24,25-(OH)2D3 simply suggests that tyrosine kinases are not involved in the
protein kinase C-dependent pathways of these factors.
The contention that the vitamin D3 metabolites activate protein kinase C via distinct
modes of action is strongly supported by the fact that actinomycin D and cycloheximide have
no effect on 1,25-(OH) 2D3-stimulated activity in growth zone chondrocytes, while both
-inhibit 24,25-(OH) 2D 3-induced activity in resting zone chondrocytes. The data suggest that
1,25-(OH)2D3 signals through a nongenomic pathway, whereas 24,25-(OH) 2D3 signal
through a genomic pathway with respect to protein kinase C-mediated events. Other
mechanisms of 24,25-(OH) 2D 3 action on resting zone chondrocytes do involve nongenomic
events (Swain et al., 1992, 1993, Schwartz et al., 1988).
The rapid effect of 1,25-(OH) 2D3 on protein kinase C in growth zone chondrocytes
suggests that it directly transduces its actions at least in part via a nongenomic mechanism. Of
course, nongenomic activation of protein kinase C may subsequently produce genomic effects.
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Others have shown that inhibition of PKC specific activity blocks 1,25-(OH) 2D3 -induced
osteocalcin production in osteoblasts (van Leeuwen et al., 1992), indicating a protein kinase
C-dependent mechanism for 1,25-(OH) 2D3 signaling in bone as well. 1,25-(OH)2D3 increases
inositol triphosphate and diacylglycerol levels in osteoblasts (Civitelli et al., 1990), suggesting
a phospholipase C-dependent mechanism. Morever, 1,25-(OH)2D3 can activate Ca+2
channels in the intestine in a process referred to as "transcaltachia" (de Boland and Norman,
1990), and protein kinase C is known to activate Ca+2 channels.
It is likely that 1,25-(OH)2D3 and 24,25-(OH) 2D3 have distinct functions in cartilage
and transduce their transmembrane signals via distinct pathways. A primary function of 1,25-
(OH) 2D 3 is to promote Ca transport (Lieberherr et al, 1989), whereas 24,25-(OH) 2D3
appears to be involved in promoting early differentiation events (de Boland and Nemere,
1992). Thus, a phospholipase C-dependent mechanism, with consequent Ca+2 transport, is
not a feature of the 24,25-(OH) 2D3 -dependent protein kinase activation. The 90 minute delay
in enzyme activation by 24,25-(OH) 2D 3 suggests that its effects are subsequent to other
regulatory events in the cell. 24,25-(OH) 2D 3 stimulates 1,25-(OH)2D3 production by resting
zone cells (Schwartz et al., 1992), causing a significant increase in 1,25-(OH) 2D3 at one hour.
While vitamin D metabolism may not account for the stimulation of PKC specific activity
observed, it does demonstrate the complex interrelationship of these factors and others in
chondrocyte regulation.
These experiments are consistent with the emerging realization that the classical steroid
hormone receptor-mediated pathway is not sufficient to explain all of the known effects of
vitamin D3 . Specifically, the action of vitamin D3 metabolites on PKC specific activity in
cultured chondrocytes is rapid and dependent upon the differentiation state of the
chondrocytes.
rhTGF-01 increases PKC specific activity in rat costochondral chondrocytes, both in the
less differentiated resting zone cells and in the more differentiated growth zone cells. Fold-
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increases in PKC specific activity generally varied from 5-30% between experiments; this
fluctuation may represent differences in TGF-P3 receptor number or other aspects of cell
maturation within each batch of primary cell cultures. Inhibitor studies verify that the kinase
activity activated by TGF-13 is in fact protein kinase C. The immunoprecipitation experiments
revealed that protein kinase C alpha is the major isoform present in untreated and rhTGF-031-
treated resting zone cells. PKC specific activity in lysates from control and rhTGF- 1-treated
cells was unaffected by antibodies specific for the beta, delta and epsilon isoenzymes, but
significantly reduced by the antibody against the alpha isoenzyme. PKC specific activity in the
TGF-1-treated cell lysates was decreased to a greater extent than in the control cells.
Unlike the more rapid responses observed for vitamin D3 metabolites, rhTGF-3 1 elicits
a dose-dependent increase in chondrocyte PKC specific activity only after six hours of
exposure in resting zone cells and nine hours of exposure in growth zone cells. In both cell
types, peak PKC specific activity was observed at 12 hours following rhTGF-3 1 exposure;
however, the increase in activity began sooner and was sustained longer in resting zone
chondrocytes. This is in contrast to the peaks at nine minutes for 1,25-(OH) 2D3 in growth
zone chondroyctes and 90 minutes for 24,25-(OH) 2D3 in resting zone chondrocytes.
The time course of protein kinase C activation by rhTGF-031 in rat costochondral
chondrocytes is not consistent with classical signal transduction events, which occur within
-minutes rather than hours. By comparison, 250pM TGF-031 has been shown to elicit more
rapid protein kinase C-dependent responses in mink lung epithelial cells (Ohtsuki and
Massague, 1992). In these cells, TGF-3 1 induced expression of junB and plasminogen
activator inhibitor-1 within 90 minutes, and their expression was completely blocked by the
protein kinase C inhibitor H7. In vascular smooth muscle cells, 4 x 10-11 M TGF-131 elicited
membrane translocation and activation of protein kinase C within 15 minutes (Wrenn et al.,
1992). Our results demonstrate no measurable effect of rhTGF-J31 upon chondrocyte PKC
specific activity before at least six hours of exposure. This observation is consistent with the
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effect of 10 ng/ml TGF-31 on phosphoinositide metabolism in Rat-1 cells (Muldoon et al.,
1988), in which inositol trisphosphate levels peaked at six hours and remained elevated at
eight hours. Interestingly, and also consistent with our findings, the effect of TGF-131 upon
inositol phosphate levels was inhibited by actinomycin D.
The long time course of rhTGF-131 action on protein kinase C in growth zone and
resting zone chondrocytes is different from other polypeptide growth factors, which often
utilize rapid phospholipase C or tyrosine kinase-dependent pathways. The insensitivity to the
phospholipase C inhibitor U73122 suggests that the rhTGF-13 1-induced PKC specific activity
does not require the action of phospholipase C on membrane phospholipids. The rhTGF-031
was co-administered with U73122 following a two-hour pretreatment with U73122 alone, and
the inhibitor remains active for at least six to eight hours (Bleasdale et al., 1989). If a
phospholipase C-dependent event were required, there would have been a reduction in PKC
specific activity, yet no significant inhibition was observed. On the contrary, in growth zone
cells, significant increases in PKC specific activity was observed at 12 hours for cultures
treated with rhTGF-131 and U73122 simultaneously.
Other pathways which utilize protein kinase C are those initiated by tyrosine kinase
transmembrane receptors such as those for epidermal growth factor (Mioh and Chen, 1989),
insulin-like growth factors (Linkhart and Keffer, 1991), and platelet-derived growth factor
(Battegay et al., 1990). Upon ligand binding, the cytoplasmic tyrosine kinase domain of these
receptors is activated, resulting in the tyrosine phosphorylation of effector molecules and
signal propagation. Failure to detect any reduction in PKC specific activity, when either
growth zone or resting zone chondrocytes was pretreated with genistein and administered
rhTGF-131 plus genistein, suggests that tyrosine kinases are not required for protein kinase C
activation by rhTGF-3 1 in costochondral chondrocytes. Autocrine production of platelet-
derived growth factor or other tyrosine kinase-associated growth factors does not appear to
be necessary for protein kinase C activation, as their actions would be inhibited by genistein.
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Nevertheless, this does not rule out the possible involvement of TGFO-induced growth factor
secretion in mesenchymal cell proliferation, nor does it rule out the possiblity that TGF-P3
initiates a cascade of growth factor production and differentiation events (Battegay et al.,
1990, Majack et al., 1990, Sporn et al., 1987').
Also consistent with the lack of early membrane-associated enzymatic effects for
rhTGF-031 is the observation of minimal translocation of protein kinase C to the cell
membrane at the time of maximal stimulation. In fact, the higher dose of rhTGF-f3 1 produced
less activity in the membrane fraction than the lower dose. This is in contrast to the 22.2-to-
28.0-fold increase in translocation observed in growth zone chondrocytes treated with 1,25-
(OH) 2D 3 or the 16.2-to-30.8-fold increases observed in resting zone cells treated with 10-9-
10-8 M 24,25-(OH)2D3. While substantial translocation was not evident, cytosolic PKC
specific activity was significantly elevated at 12 hours, suggesting a distinct mechanism of
activation by rhTGF-3 1 compared to that seen with the vitamin D metabolites. The dose-
dependent increase in cytosolic, rather than membrane, protein kinase C, suggests that TGFP3
may stimulate basal enzyme production via a genomic mechanism. Subsequently, other
agents, acting through nongenomic mechanisms, may enhance membrane translocation of this
increased reserve of protein kinase C. It is also possible that at later time points the elevated
cytosolic enzyme would have been translocated to the membrane.
Our results indicated major differences in the time course, biochemical pathway, and
subcellular localization of protein kinase C activation by rhTGF-0 1, all of which are consistent
with a genomic, rather than a nongenomic, effect. The Western blot also suggests that
rhTGF-031 treatment may increase the relative amount of protein kinase C protein present in
the culture, indicating a genomic mechanism of action. Interestingly, the modest increase in
band intensity observed is apparently sufficient for the substantial increase in activity obtained.
This hypothesis was supported by the reduction of PKC specific activity observed in cultures
treated with rhTGF-01 in conjunction with the transcription inhibitor actinomycin D or the
60
translation inhibitor cycloheximide. When compared at equimolar amounts, actinomycin D
always produced slightly more inhibition than cycloheximide in both types of chondrocytes.
These data strongly suggest that de novo RNA and protein synthesis are both required for
TGF3-induced PKC specific activity.
In summary, these experiments have shown that PKC specific activity is regulated by
TGFO3 in costochondral chondrocytes in a time-dependent and cell maturation specific manner.
The mechanism of activation does not appear to involve either phospholipase C or tyrosine
kinase activity; however, new gene transcription and translation are involved. The results
suggest that the TGFI3 effects on protein kinase C are the result of a regulatory cascade.
Increased cytosolic enzyme activity may serve as a reservoir for non-genomic translocation of
protein kinase C in response to other regulatory factors or as a downstream event in the TGF
03-dependent stimulation of the enzyme.
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